The WACC of Tissue Regenix Group PLC (TRX.L) is 11.4%.
| Range | Selected | |
| Cost of equity | 11.00% - 24.20% | 17.60% |
| Tax rate | 4.30% - 6.40% | 5.35% |
| Cost of debt | 7.00% - 9.60% | 8.30% |
| WACC | 8.3% - 14.6% | 11.4% |
| Category | Low | High |
| Long-term bond rate | 4.0% | 4.5% |
| Equity market risk premium | 6.0% | 7.0% |
| Adjusted beta | 1.17 | 2.75 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 11.00% | 24.20% |
| Tax rate | 4.30% | 6.40% |
| Debt/Equity ratio | 1.72 | 1.72 |
| Cost of debt | 7.00% | 9.60% |
| After-tax WACC | 8.3% | 14.6% |
| Selected WACC | 11.4% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for TRX.L:
cost_of_equity (17.60%) = risk_free_rate (4.25%) + equity_risk_premium (6.50%) * adjusted_beta (1.17) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.